Avalon Globocare Corp (ALBT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ALBT Chart
Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?
Avalon GloboCare (NASDAQ: ALBT ) stock is up on Wednesday alongside news of a new medical device being launched by Laboratory Services MSO. Laboratory Services MSO is preparing to launch its GeeWhiz External Condom Catheter in the third quarter of 2024.
Why Is Avalon Globocare (ALBT) Stock Down 27% Today?
Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the company filed its Form 10-Q with the Securities and Exchange Commission (SEC).
Avalon Globocare Corp Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Leanne Menzel Smallwood Wealth Investment Management LLC | 5 | $24 | $1.33 | -$22.67 | -94.46% |
| SAM Smartleaf Asset Management LLC Smartleaf Asset Management LLC | 1 | $1.2 | $0.29 | -$0.91 | -75.83% |
Avalon Globocare Corp (ALBT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Avalon Globocare Corp ever had a stock split?
Avalon Globocare Corp Profile
| Health Care Providers & Services Industry | Healthcare Sector | Meng Li CEO | NASDAQ (CM) Exchange | 05344R302 CUSIP |
| US Country | 2 Employees | - Last Dividend | 28 Oct 2024 Last Split | 6 Dec 2016 IPO Date |
Overview
Avalon GloboCare Corp., along with its subsidiaries, is a diversified healthcare and real estate company based in Freehold, New Jersey. Founded in 2016, it operates both in the United States and China, managing commercial real estate properties. The company is notable for its involvement in the development and delivery of transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon GloboCare is actively engaged in advancing a variety of innovative therapeutic and diagnostic approaches, focusing particularly on cellular therapies, mRNA-based treatments, and exosome technology.
Products and Services
- AVA-001: An anti-CD19 CAR-T cellular therapy that has completed initial human clinical trials for treating relapsed/refractory (R/R) B-cell lymphoblastic leukemia. This indicates a significant step forward in Avalon's commitment to offering new cancer treatments.
- AVA-011: Currently in the IND-enabling process development stage, this therapy has completed pre-clinical laboratory studies. It is designed to generate cGMP-grade AVA-011 CAR-T cells, pushing forward the boundaries of cellular therapy for patients.
- mRNA-based Flash-CAR cell therapy platform: This platform represents Avalon's foray into the rapidly evolving field of mRNA therapeutics, focusing on developing next-generation cellular therapies.
- Avalon clinical-grade tissue-specific exosome (ACTEX): Focuses on leveraging exosome technology for therapeutic applications, showcasing Avalon’s commitment to exploring the potential of exosomes in medicine.
- AVA-Trap: A therapeutic program aimed at combating COVID-19 and other critical conditions associated with cytokine storms. This reflects Avalon's dedication to addressing immediate and pressing global health challenges.
- QTY-code protein design technology collaboration with MIT: This partnership focuses on the development of therapeutic and diagnostic targets, including the creation of a hemofiltration device to treat Cytokine Storm, showcasing the company's investment in innovative technologies.
- Co-development with Arbele Limited: This strategic collaboration aims to advance next-generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities, highlighting Avalon’s strategy of partnership in innovation.
- Strategic partnership with HydroPeptide, LLC: Engages in the co-development and commercialization of clinical-grade, exosome-based cosmeceutical, and orthopedic products, illustrating Avalon's versatility and its cross-sectoral collaborative efforts.
- Corporate research agreement with the University of Pittsburgh: This agreement centers around advancing Avalon’s product development efforts, emphasizing the company’s commitment to research and innovation in collaboration with leading academic institutions.
